Bromocriptine monotherapy of a prolactinoma causing erectile dysfunction
López Cubillana, P.; Hita Rosino, E.; Asensio Egea, L.; Rigabert Montiel, M.; Hita Villaplana, G.; Server Pastor, G.; Server Falgás, G.
Archivos Espanoles de Urologia 50(5): 526-528
1997
ISSN/ISBN: 0004-0614 PMID: 9382597 Document Number: 473054
A case of erectile dysfunction in a patient with prolactinoma is described herein. The literature on the incidence, diagnosis and therapeutic management of this condition is reviewed. Impotence may arise from several causes. It is widely accepted that 30-50% have an organic etiology, with vascular involvement being more prevalent than other causes (neurological, endocrinological, urological, iatrogenic, pharmacological, systemic diseases). Hyperprolactinemia, arising from a prolactinoma, is one of the endocrinological conditions causing impotence. In men, this endocrinological disorder is rarely accompanied by other clinical anomalies, such as gynecomastia, galactorrhea or signs of a pituitary tumor. The patient described herein presented with erectile dysfunction. During evaluation, he was found to be hyperprolactinemic. Subsequent assessment disclosed a pituitary adenoma. The patient was successfully treated with bromocriptine. Erectile dysfunction arising from hyperprolactinemia is uncommon. Serum prolactin levels, a lateral skull x-ray and CT/MRI are essential in the diagnosis and treatment of this condition. Treatment must be directed at the underlying cause. Bromocriptine has proved to be effective and carries a low risk of undesired effects.